来自官方财务报表的收入、利润与现金流历史。
布鲁克公司及其子公司开发、制造和分销科学仪器以及分析和诊断解决方案。该公司通过四个部门运营：Bruker Scientific Instruments (BSI) BioSpin、BSI CALID、BSI Nano 和 Bruker Energy & Supercon Technologies。该公司提供磁共振波谱、临床前成像、生物制药和应用、服务和生命周期支持、集成数据解决方案和自动化；生命科学工具；创新的核磁共振（NMR）和电子顺磁共振（EPR）产品；体内过程和药物发现的解决方案；售后解决方案；实验室自动化和数字化解决方案；质谱解决方案和检测试剂盒、DNA 试纸条以及基于荧光的 PCR 技术；基因型和荧光型分子诊断试剂盒；以及研究、分析和过程分析仪器和解决方案。它还提供一系列便携式分析和生物分析检测系统以及相关产品； X射线仪器；电子显微镜分析工具，以及手持式、便携式和移动式X射线荧光光谱仪；原子力显微镜仪器；非接触式纳米分辨率溶液形貌；自动化 X 射线计量、自动化 AFM 缺陷检测以及光掩模修复和清洁设备。此外，该公司还提供先进的光学荧光显微镜仪器；转录分析和多组学分析服务；超导材料，例如金属低温超导体；单片和线槽形式的多丝圆形和矩形 LTS 线材；设计和制造 Cuponal；金属低温超导体；和非支持
机器翻译
| 利润表 | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 总收入 | $3.5B | $3.4B | $3.4B | $3.0B | $2.5B | $2.4B | $2.0B | $2.1B | $1.9B | $1.8B | $1.6B | $1.6B | $1.8B | $1.8B | $1.8B | $1.7B | $1.3B | $1.1B | $1.1B | $548M | $436M |
| 毛利 | $1.6B | $1.6B | $1.6B | $1.5B | $1.3B | $1.2B | $940M | $995M | $900M | $813M | $742M | $709M | $763M | $805M | $831M | $752M | $606M | $519M | $505M | $253M | $199M |
| 毛利率% | 46.7% | 45.9% | 49.0% | 51.0% | 51.6% | 50.0% | 47.3% | 48.0% | 47.5% | 46.0% | 46.1% | 43.6% | 42.2% | 43.8% | 46.4% | 45.6% | 46.4% | 46.5% | 45.6% | 46.2% | 45.7% |
| 营业利润（EBIT） | — | $236M | $253M | $437M | $433M | $413M | $248M | $301M | $262M | $215M | $177M | $146M | $105M | $148M | $156M | $156M | $156M | $137M | $108M | $50M | $31M |
| 营业利润率% | — | 6.9% | 7.5% | 14.7% | 17.1% | 17.1% | 12.5% | 14.5% | 13.8% | 12.2% | 11.0% | 9.0% | 5.8% | 8.1% | 8.7% | 9.4% | 11.9% | 12.3% | 9.8% | 9.1% | 7.0% |
| 净利 | ($72M) | ($9M) | $113M | $427M | $297M | $277M | $158M | $197M | $180M | $79M | $154M | $102M | $57M | $80M | $78M | $92M | $95M | $81M | $65M | $32M | $18M |
| 净利润率 % | -2.1% | -0.2% | 3.4% | 14.4% | 11.7% | 11.5% | 7.9% | 9.5% | 9.5% | 4.5% | 9.5% | 6.3% | 3.1% | 4.3% | 4.3% | 5.6% | 7.3% | 7.3% | 5.9% | 5.8% | 4.2% |
| EBITDA | — | $303M | $439M | $676M | $519M | $497M | $321M | $372M | $340M | $300M | $262M | $229M | $216M | $239M | $212M | $206M | $156M | $166M | $135M | $63M | $50M |
| 每股收益（EPS） | — | $-0.06 | $0.76 | $2.90 | $1.99 | $1.81 | $1.02 | $1.26 | $1.14 | $0.49 | $0.95 | $0.60 | $0.33 | $0.48 | $0.46 | $0.55 | $0.58 | $0.49 | $0.39 | $0.19 | $0.18 |
| 已发行股数 (M) | — | 152M | 150M | 147M | 149M | 153M | 155M | 157M | 157M | 159M | 162M | 169M | 170M | 168M | 167M | 167M | 166M | 165M | 166M | 164M | 103M |
来源：公司公开报告（SEC）。在依赖任何数字前请核对 SEC EDGAR。
资产负债表、现金流、季度数据与完整财务比率见 BRKR 交互式查看器。 /companies/us/BRKR
本网站信息仅用于教育与参考，不构成投资建议。不发布目标价或买卖建议。
About TickerBase · Data methodology & sources · Privacy · Terms